Efficacy, Safety LactiSal 1% Gel, LactSal 50 mg, Clotrimazole 100 mg Tablet in Treatment Vulvovaginal Candidiasis

Exclusion Criteria

• •Recurrent VVC (4 episodes of VVC in the past 12 months).
• •Women with other vaginal infections, e.g. bacterial vaginosis, aerobic vaginitis, trichomoniasis, and mixed infections.
• •Women using oral or vaginal antifungals within 2 weeks prior to enrolment.
• •Women using any intra-vaginal products, also vaginal douches containing soaps and other anionic, surface-active substances, within 2 weeks prior to enrolment.
• •Women using any antibiotic or anti-infective within 2 weeks prior to enrolment.
• •Women having menstruation bleeding at enrolment
• •Cervicitis, cervical erosions, and malignant tumours in the genital tract
• •Pregnancy or lactation.
• •Women not consenting to be sexually abstinent during the treatment, not taking oral contraceptive or not having an IUD for contraception
• •Woman using intravaginal pessaries, rings, sponges or diaphragms
• •Severe systemic diseases (diabetes mellitus, cancer, tuberculosis, autoimmune diseases, severe psychiatric conditions, etc.).
• •Women with confirmed or suspected STD (HIV infection, gonorrhoea, syphilis, chlamydiasis, etc.).
• •Known or suspected hypersensitivity to one of the study medications, inclusive their excipients.
• •Participation of patient in another clinical study concomitantly or within 30 days prior to enrolment
• •Patient is relative of, or staff directly reporting to, the investigator.